ABSTRACT
ABSTRACT: The role of chemotherapy in thyroid cancer has been disappointing. Doxorubicin is the only systemic agent approved for the treatment of thyroid cancer in the United States and Europe, but with limited efˆcacy, both in differentiated and medullary thyroid cancer. The adjunct of other antiblastic treatment has been explored in small studies, with con°icting results. Nevertheless, the integration of chemotherapy with new treatment modalities, along with a better deˆnition of optimal timing of administration, identiˆcation of more sensitive histologies, and the development of appropriate protocols, could expand the importance of this treatment. In anaplastic thyroid carcinoma, chemotherapy may be considered for radiosensitization after complete resection and also as palliative therapy in metastatic or recurrent disease.
